Medicilon Logo
search icon search icon language icon contact icon menu icon
Medicilon Logo
search icon close search icon language icon contact icon menu icon
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon's News information
News information

Lyme Diseases May Be Diagnosable via Transcriptome Signature

Page View:

    Lyme disease is critical to detect at an early stage in order to prevent complications like, “arthritis, meningitis, facial palsy, and, in rare cases, myocarditis, or damage to heart muscle leading to sudden death”. However, researchers know that lyme can hide during the window period of infection before a detectable antibody response. So, scientists at the University of California, San Francisco, “decided to look for signs of Lyme disease not in the antibody response, but in the transcriptome, which amounts to the full range of messenger RNA molecules that is produced by a particular cell or tissue type”.

    The UCSF scientists, led by Charles Chiu, M.D., Ph.D., used a next-generation sequencing technique, called RNA-seq, to investigate the transcriptome in peripheral blood mononuclear cells. In the white blood cells of patients infected with tick-borne bacteria, the scientists found a distinctive pattern in the transcriptome—a gene expression signature.

    The details of this work appeared February 12 in the journal mBio, in an article entitled “Longitudinal Transcriptome Analysis Reveals a Sustained Differential Gene Expression Signature in Patients Treated for Acute Lyme Disease.” The article describes how the tesearchers examined 29 patients before and after they received a three-week course of antibiotic treatment and also six months later. Compared to patients with other active bacterial or viral infections, the Lyme disease patients had distinctive gene signatures that persisted for at least three weeks, even after they had taken the antibiotics. Some differences in the transcriptome lingered for six months.

    “Early Lyme disease prior to antibiotic therapy was characterized by marked upregulation of Toll-like receptor signaling but lack of activation of the inflammatory T-cell apoptotic and B-cell developmental pathways seen in other acute infectious syndromes,” wrote the study’s authors. “Six months after completion of therapy, Lyme disease patients were found to have 31 to 60% of their pathways in common with three different immune-mediated chronic diseases. No differential gene expression signature was observed between Lyme disease patients with resolved illness to those with persistent symptoms at six months post-treatment.”

    Six months after treatment, 15 of the 29 patients in the study had fully recovered, while 13 had persistent symptoms, and one had dropped out. Despite the stark differences in how the patients reported feeling, the researchers could not detect transcriptional differences between the two groups. They said larger studies are needed to confirm this finding.

    Researchers found similarities between the transcriptional changes after Lyme disease infection and other diseases. The acute phase of Lyme disease infection had similarities with influenza. At six months, the gene signatures of Lyme disease patients showed some similarities to those from patients with immune diseases like systematic lupus erythematosus, rheumatoid arthritis, and chronic fatigue syndrome.

    The researchers were also interested in looking for the molecular pathways by which Lyme disease causes long-term symptoms. “This study,” the researchers noted, “uncovered multiple previously undescribed pathways and genes that may be useful in the future as human host biomarkers for diagnosis, and that constitute potential targets for the development of new therapies.”

    “To our knowledge, this study is the first to document changes in gene expression occurring even after a bacterial infection has been treated with appropriate antibiotics,” said John Aucott, M.D., assistant professor of medicine at the Johns Hopkins University School of Medicine and a senior investigator on the study.

    The discovery of a gene expression signature of Lyme disease is especially welcome in light of a finding, reported last month in the Journal of Medical Entomology that the range of Lyme disease–carrying ticks is spreading. This report focused on the blacklegged tick (Ixodes scapularis) and the western blacklegged tick (Ixodes pacificus) and indicated that these species were more widespread than they were two decades ago, the last time a major survey had been conducted.

    The new survey found that the blacklegged tick has been reported in more than 45% of U.S. counties, compared to 30% of counties in 1998. Even more alarming, the blacklegged tick is now considered established in twice the number of counties as in 1998.

    Most of the geographic expansion of the blacklegged tick appears to be in the northern United States, while populations in southern states have remained relatively stable. The range of the western blacklegged tick only increased from 3.4% to 3.6% of counties.

Relevant newsRelevant news